Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Lenvatinib Mesylate

These are related to the Lenvatinib Mesylate news, in which you can learn about the updated information in Lenvatinib Mesylate, to help you better understand and expand Lenvatinib Mesylate market. Because the market for Lenvatinib Mesylate is evolving and changing, so we recommend that you collect our website, and we will show you the latest news on a regular basis.
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 16 2024

    Drug Patent & Exclusivity Expiration Report - Week of Dec 16 2024

    2024-12-16

    This week, there are 16 drugs in the patent and exclusivity list. They are: - UNITED THERAPEUTICS CORP's REMODULIN, containing active ingredient TREPROSTINIL - VALINOR PHARMA LLC's MOVANTIK, containing active ingredient NALOXEGOL OXALATE - OTSUKA PHARMACEUTICAL CO LTD's ABILIFY, containing active ingredient ARIPIPRAZOLE - INTRA-CELLULAR THERAPIES INC's CAPLYTA, containing active ingredient LUMATEPERONE TOSYLATE - PFIZER INC's TOVIAZ, containing active ingredient FESOTERODINE FUMARATE - CUBIST PHARMACEUTICALS LLC's ZERBAXA, containing active ingredient CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - EISAI INC's LENVIMA, containing active ingredient LENVATINIB MESYLATE - PF PRISM CV's BOSULIF, containing active ingredient BOSUTINIB MONOHYDRATE - AMGEN INC's OTEZLA, containing active ingredient APREMILAST Read More